Skip to main content
Erschienen in: Orphanet Journal of Rare Diseases 1/2015

Open Access 01.12.2015 | Letter to the Editor

High prevalence of hyposalivation in individuals with neurofibromatosis 1: a case–control study

verfasst von: Karin Soares Cunha, Rafaela Elvira Rozza-de-Menezes, Eloá Borges Luna, Lilian Machado de Sousa Almeida, Raquel Richelieu Lima de Andrade Pontes, Paula Nascimento Almeida, Letícia Vidaurre de Aguiar, Eliane Pedra Dias

Erschienen in: Orphanet Journal of Rare Diseases | Ausgabe 1/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Neurofibromatosis type 1 (NF1) is one of the most common genetic diseases in humans and has widely variable expressivity. Oral manifestations are common, but there are no studies that investigated functional alterations in salivary glands in NF1. Our aim was to evaluate the salivary flow rate in NF1 individuals, comparing to a control group, and to investigate the possible causes and some consequences of salivary gland alteration.

Methods

This is a case–control study that evaluated the salivary flow rate of NF1 individuals (n = 49) and compared to an age and sex-matched control group. We have also investigated the possible causes and consequences of hyposalivation in NF1 individuals through anamnesis, a specific questionnaire, physical examination, tongue coating evaluation and cytopathological exam to assess the prevalence of oral candidiasis.

Results

Hyposalivation at rest was present in 59% (29/49) of NF1 individuals in contrast to 22% (11/49) in the control group, being statistically significant (P <0.0001; Wilcoxon rank-sum test). The analysis of the adjusted residual showed that the prevalence of hyposalivation in NF1 individuals (46.9%) was 4-fold higher than in controls (10.2%). None of the possible causes of hyposalivation (medications, low liquid intake, caffeinated or stimulant drink use, mouth breathers, alcohol, smoke and plexiform neurofibroma close to or involving major salivary glands areas) had important impact on the salivary flow rate in NF1 individuals.

Conclusions

Hyposalivation may be a consequence of NF1, as occurs in other genetic diseases. More studies are necessary to understand if there is and what is the relationship between NF1 and hyposalivation.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13023-015-0239-4) contains supplementary material, which is available to authorized users.

Competing interests

The authors declared that they have no competing interests.

Authors’ contributions

KSC designed the project, supervised and coordinated the whole process and wrote the manuscript. RRLAP and LVA attended the NF1 participants and collected the data from this group. RRLAP and EBL performed the tongue coating index analysis. EBL, PNA and LMAS obtained the data from the control group. RERM, PNA and EBL participated in writing the manuscript. RERM were involved in statistical analysis and data interpretation. EPD was responsible for cytopathology analysis and critically reviewed the manuscript. All authors read and approved the final manuscript.
Abkürzungen
NF1
Neurofibromatosis 1
TCI
Tongue coating index
UWSFR
Unstimulated whole saliva flow rate
OR
Odds ratio
IC
Confidence interval

Background

Neurofibromatosis 1 (NF1, OMIM 162200) is one of the most common genetic diseases and has widely variable expressivity [1]. Oral manifestations are common, [2-6] but there are no studies that investigated functional alterations in salivary glands in NF1. Our aim was to evaluate the salivary flow rate in NF1 individuals, comparing to a control group, and to investigate the possible causes and some consequences of salivary gland alteration.

Methods

This case–control study was approved by the Ethics Committee (#31640/2012) and conducted at Oral Diagnosis Ambulatory and Pathological Anatomy Service of Antônio Pedro University Hospital of Universidade Federal Fluminense, Brazil.
The study group was composed of 49 NF1 individuals, according to clinical criteria [7]. To compare the sialometry values of NF1 individuals, a sex and age-matched control group (n=49) composed by non-NF1 individuals was included. Data about smoking, alcohol use, and intake of hyposalivation-inducing drugs was obtained from both groups.
Sialometry (unstimulated whole saliva flow rate) was performed between 8:00–11:30 AM and the participants did not ingest food or liquids 1 hour before the exam. After discarding all the saliva present in the mouth, saliva was collected for 5 minutes without stimulus. The salivary flow rate (mL/min) was calculated and classified: normal: ≥0.3; low: ≥0.1 and <0.3; very low: <0.1.
Tongue coating was evaluated according to previous studies [8,9], using digital photographs. The tongue dorsum area was divided into nine equal sections and each section was assigned a value: 0 = no; 1 = thin, 2 = thick coating. The sum of the results of each section was calculated, divided by 18 and multiplied by 100 to achieve the tongue coating index (TCI) percentage score.
Oral candidiasis was investigated by clinical and cytopathology exam through scrapping the tongue dorsum with a cytobrush. Glass slides stained with Papanicolaou and Periodic Acid-Schiff were analyzed according to specific criteria [10].
NF1 participants also answered to a questionnaire (Table 1).
Table 1
Questionnaire used in the study group (with NF1)
Questions
Response
Oral Dryness Questionnaire
Yes
No
1. Do you fell dry oral mucosa sensation?
Yes
No
2. Do you feel dry lips sensation?
Yes
No
3. Do you have difficult to swallow dry food?
Yes
No
4. Do you drink liquids to aid swallowing dry food?
Yes
No
5. Do you feel change in saliva viscosity?
Yes
No
6. Do you feel a decreased amount of saliva in your mouth?
Yes
No
7. Do you feel enough or increased amount of saliva in your mouth?
Yes
No
Other Questions
Yes
No
8. Do you intake at least 2 liters of liquid daily?
Yes
No
9. Do you commonly drink caffeinated or stimulant drinks?
Yes
No
10. You are a mouth breather?
Yes
No

Results

Additional files 1, 2 and 3 show details of the results. Table 2 summarizes the sample characteristics. There was no heterogeneity between the study and control group according to smoking, alcohol use and intake of medications that could cause hyposalivation. Four (8%) NF1 participants had plexiform neurofibromas close to or involving the major salivary glands areas and only one (25%) had hyposalivation.
Table 2
Summary of the sample characteristics
Data
Study group (with NF1)
Control group
P *
Number
49
49
 
Age (years)
42.5 ± 14.8
42.5 ± 14.8
Sex (female/male)
35/14 (2.5:1.0)
35/14 (2.5:1.0)
Smoker
4 (8%)
9 (18%)
0.227
Alcohol user
8 (16%)
10 (20%)
0.774
Hyposalivation-inducing drugs
14 (28%)
18 (36%)
0.344
NF1, Neurofibromatosis 1.
*P value is from McNemar χ2 test; Results indicate mean ± standard deviation.
In NF1 individuals, 59% (29/49) had hyposalivation; 32% (16/49) had severe hyposalivation. In the control group, 22% (11/49) of individuals had hyposalivation; 8% (4/49) presented severe hyposalivation. There was a statistically significant difference between the sialometry values of the study and control group (P < 0.0001; Wilcoxon rank-sum test). There was a statistically significant association between NF1 individuals and presence of hyposalivation (P = 0.001; McNemar’s χ2 test). The analysis of the adjusted residual showed that the prevalence of hyposalivation in NF1 individuals (46.9%) was 4-fold higher than in controls (10.2%).
Forty-six NF1 participants answered to the questionnaire. The number of positive answers per individual to the oral dryness questions was assessed to investigate them as possible predictor of hyposalivation. The results are shown in Tables 34.
Table 3
Hyposalivation and oral dryness questionnaire in study group (with NF1)
Oral Dryness Assessment Questionnaire
UWSFR
Hyposalivation (%)
OR (IC 95%)
P *
1. Do you fell dry oral mucosa sensation?
9 (18)
1.8 (0.4 – 7.3)
0.51
2. Do you feel dry lips sensation?
10 (20)
0.8 (0.2 – 2.6)
0.76
3. Do you have difficult to swallow dry food?
6 (12)
1.5 (0.3 – 7)
0.71
4. Do you drink liquids to aid swallowing dry food?
14 (28)
1.8 (0.5 – 6.1)
0.37
5. Do you feel change in saliva viscosity?
11 (22)
1.9 (0.5 – 6.9)
0.36
6. Do you feel a decreased amount of saliva in your mouth?
8 (16)
0.9 (0.2 – 3.2)
0.88
7. Do you feel enough or increased amount of saliva in your mouth?
3 (6)
0.4 (0.09 – 2)
0.42
UWSFR, unstimulated whole saliva flow rate; OR (IC 95%), Odds ratio and 95% of confidence interval.
*P value is from Qui-Square analysis or Fisher’s exact test.
Table 4
Score of positive answers from oral dryness assessment questionnaire according to hyposalivation in study group (with NF1)
Number of positive answers*
UWSFR
Hyposalivation (%)
OR (IC 95%)
P **
None
7 (14)
0.9 (0.2 – 3.7)
0.97
One
8 (16.3)
0.6 (0.1 – 3)
0.7
Two
4 (8.1)
0.4 (0.1 – 2.1)
0.45
Three
7 (14)
2.9 (0.5 – 16.2)
0.27
Four
2 (4)
1.7 (1.3 – 2.2)
0.5
Five
2 (4)
1.4 (0.1 – 17.1)
1.0
Six
2 (4)
0.6 (0.8 – 5.3)
1.0
UWSFR, Unstimulated whole saliva flow rate; OR (IC 95%), Odds ratio and 95% of confidence interval.
*Considering the first six questions of the Oral Dryness Questionnaire, **P value is from Qui-Square analysis or Fisher’s exact test.
Oral candidiasis was present in 22% (11/49) of NF1 individuals. Of these, 54% (6/49) had no clinical signs or symptoms of candidiasis, 36% (3/49) had erythematous and 9% (1/49) pseudomembranous candidiasis.
Fifty-five percent (27/49) of NF1 individuals had more than 50% and 16% had more than 80% of the tongue covered by coating. The mean of TCI was 50% (standard deviation = 26.7, median = 50, first quartile = 25, third quartile = 72).
Any of the investigated variables were associated with hyposalivation in NF1 individuals (Table 5).
Table 5
Correlation between hyposalivation and its causes and consequences in study group (with NF1)
Variables
Hyposalivation
UWSFR
OR (95% IC)
P *
Age
43 ± 15.6
0.77
Female/Male
23/6 (3.8/1)
2.5 (0.7-9.0)
0.14
Plexiform neurofibroma close to or involving major salivary glands areas
1 (3.4%)
0.2 (0.01-2.1)
0.29
Smoker
1 (3.4%)
0.2 (0.01-2.1)
0.29
Alcohol user
5 (17%)
1.1 (0.2-5.6)
1.0
Hyposalivation-inducing drugs
15 (51%)
1.6 (0.5-5.0)
0.41
Intake less than 2 liters of liquid daily
8 (27%)
1.7 (0.5-5.6)
0.36
Caffeinated or stimulant drink use
13 (44%)
1.2 (0.3-4.1)
0.68
Mouth breather
14 (48%)
1.4 (0.4-4.8)
0.51
Oral candidiasis
7 (24%)
1.2 (0.3-5.0)
1.0
Tongue coating index
44.4 ± 27.3
0.05
UWSFR, Unstimulated whole saliva flow rate; OR (95% IC), Odds ratio and 95% of confidence interval.
*P value is from Qui-square analysis and Fisher’s exact tests for categorical variables and Mann–Whitney test for numerical variables; Results of age and tongue coating index indicate mean ± standard deviation.

Discussion

We showed that NF1 individuals present high prevalence (59%) of hyposalivation comparing to a control group (P < 0.001), with a proportion 4-fold higher than the controls.
Xerostomia often occurs when sialometry value is reduced by about 50% [11]. Due to this lack of correlation between xerostomia and hyposalivation, some authors have investigated whether positive answers to other questions related to the dry mouth symptoms have correlation with sialometry values [11]. In our study, hyposalivation was not associated with xerostomia in NF1 individuals, neither with other questions from the oral dryness questionnaire.
Xerostomia can also occur in individuals with normal sialometry values [11,12]. It can occur in mouth breathers or because of changes in the sialochemistry, viscoelastic properties of saliva or by sensory alterations. In the present study, there was no NF1 individual who complained of xerostomia and did not present hyposalivation.
Saliva exerts many functions in oral cavity, including the control of the composition of the microflora. We found 22% of NF1 participants with cytological evidence of oral candidiasis and 55% with 50% of the tongue covered by coating, but none were associated with hyposalivation.
None of the investigated causes of hyposalivation (medications, low liquid intake, caffeinated or stimulant drink use, alcohol, and smoke) were associated with low salivary flow rate in NF1. Moreover, only 4 (8%) NF1 individuals had plexiform neurofibromas in areas of major salivary glands, which could cause atrophy of the acinar cells by compression or infiltration by the tumor cells, and just one of them had hyposalivation.
Alterations in the salivary glands (acini and ducts) caused by mutations in the NF1 gene may be a possible explanation for the high prevalence of hyposalivation in NF1 individuals. Neurofibromin is a negative regulator of the Ras pathways and there is a complex signaling cross-talks between neurofibromin and other members of the superfamily of small GTPases, including Rho binding domain [13]. Rho family of small GTPases presents a crucial role in lumen morphogenesis of salivary glands in animal models and in acinus formation in human salivary gland cell line [13-16]. Kimura et al. [17] showed that neurofibromin is strongly expressed in ductal cells of the parotids. Other salivary glands were not evaluated in that study.
Moreover, the volume and type of saliva is controlled by autonomic nervous system and the blood supply to the glands influences the salivary secretion. Since neurofibromin is expressed in peripheral and central nervous system, as well as in blood vessel smooth muscle and endothelial cells [18-20], alteration in autonomic nervous system and in blood flux to the salivary glands may also be involved in hyposalivation in NF1 individuals.

Conclusions

Hyposalivation may be a consequence of NF1, as occurs in other genetic diseases. More studies are necessary to understand if there is and what is the relationship between NF1 and hyposalivation.

Availability of supporting data

The data sets supporting the results of this article are included within the paper and its additional files.

Acknowledgment

The authors thank the Postgraduate Program in Pathology of Universidade Federal Fluminense for its most valuable Oral Diagnosis Ambulatory, which made possible the attendance of NF1 participants. The present research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declared that they have no competing interests.

Authors’ contributions

KSC designed the project, supervised and coordinated the whole process and wrote the manuscript. RRLAP and LVA attended the NF1 participants and collected the data from this group. RRLAP and EBL performed the tongue coating index analysis. EBL, PNA and LMAS obtained the data from the control group. RERM, PNA and EBL participated in writing the manuscript. RERM were involved in statistical analysis and data interpretation. EPD was responsible for cytopathology analysis and critically reviewed the manuscript. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Cunha KSG, Geller M. Advances in Neurofibromatosis Research. New York: Nova Science Publishers Inc; 2011. Cunha KSG, Geller M. Advances in Neurofibromatosis Research. New York: Nova Science Publishers Inc; 2011.
2.
Zurück zum Zitat Shapiro SD, Abramovitch K, Van Dis ML, Skoczylas LJ, Langlais RP, Jorgenson RJ, et al. Neurofibromatosis: oral and radiographic manifestations. Oral Surg Oral Med Oral Pathol. 1984;58:493–8.CrossRefPubMed Shapiro SD, Abramovitch K, Van Dis ML, Skoczylas LJ, Langlais RP, Jorgenson RJ, et al. Neurofibromatosis: oral and radiographic manifestations. Oral Surg Oral Med Oral Pathol. 1984;58:493–8.CrossRefPubMed
3.
Zurück zum Zitat Cunha KS, Barboza EP, Dias EP, Oliveira FM. Neurofibromatosis type I with periodontal manifestation. A case report and literature review. Br Dent J. 2004;196:457–60.CrossRefPubMed Cunha KS, Barboza EP, Dias EP, Oliveira FM. Neurofibromatosis type I with periodontal manifestation. A case report and literature review. Br Dent J. 2004;196:457–60.CrossRefPubMed
4.
Zurück zum Zitat D’Ambrosio JA, Langlais RP, Young RS. Jaw and skull changes in neurofibromatosis. Oral Surg Oral Med Oral Pathol. 1988;66:391–6.CrossRefPubMed D’Ambrosio JA, Langlais RP, Young RS. Jaw and skull changes in neurofibromatosis. Oral Surg Oral Med Oral Pathol. 1988;66:391–6.CrossRefPubMed
5.
Zurück zum Zitat Bardellini E, Amadori F, Flocchini P, Conti G, Piana G, Majorana A. Oral findings in 50 children with neurofibromatosis type 1. A case control study. Eur J Paediatr Dent Off J Eur Acad Paediatr Dent. 2011;12:256–60.CrossRef Bardellini E, Amadori F, Flocchini P, Conti G, Piana G, Majorana A. Oral findings in 50 children with neurofibromatosis type 1. A case control study. Eur J Paediatr Dent Off J Eur Acad Paediatr Dent. 2011;12:256–60.CrossRef
6.
Zurück zum Zitat Javed F, Ramalingam S, Ahmed HB, Gupta B, Sundar C, Qadri T, et al. Oral manifestations in patients with neurofibromatosis type-1: a comprehensive literature review. Crit Rev Oncol Hematol. 2014;91:123–9.CrossRefPubMed Javed F, Ramalingam S, Ahmed HB, Gupta B, Sundar C, Qadri T, et al. Oral manifestations in patients with neurofibromatosis type-1: a comprehensive literature review. Crit Rev Oncol Hematol. 2014;91:123–9.CrossRefPubMed
7.
Zurück zum Zitat Stumpf DA, Alksne JF, Annegers JF, Brown SS, Conneally PM, Housman D, et al. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575–8.CrossRef Stumpf DA, Alksne JF, Annegers JF, Brown SS, Conneally PM, Housman D, et al. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575–8.CrossRef
8.
Zurück zum Zitat Mantilla Gómez S, Danser MM, Sipos PM, Rowshani B, van der Velden U, van der Weijden GA. Tongue coating and salivary bacterial counts in healthy/gingivitis subjects and periodontitis patients. J Clin Periodontol. 2001;28:970–8.CrossRefPubMed Mantilla Gómez S, Danser MM, Sipos PM, Rowshani B, van der Velden U, van der Weijden GA. Tongue coating and salivary bacterial counts in healthy/gingivitis subjects and periodontitis patients. J Clin Periodontol. 2001;28:970–8.CrossRefPubMed
9.
Zurück zum Zitat Shimizu T, Ueda T, Sakurai K. New method for evaluation of tongue-coating status. J Oral Rehabil. 2007;34:442–7.CrossRefPubMed Shimizu T, Ueda T, Sakurai K. New method for evaluation of tongue-coating status. J Oral Rehabil. 2007;34:442–7.CrossRefPubMed
10.
Zurück zum Zitat Picciani BLS, Silva-Junior GO, Michalski-Santos B, Avelleira JCR, Azulay DR, Pires FR, et al. Prevalence of oral manifestations in 203 patients with psoriasis. J Eur Acad Dermatol Venereol JEADV. 2011;25:1481–3.CrossRef Picciani BLS, Silva-Junior GO, Michalski-Santos B, Avelleira JCR, Azulay DR, Pires FR, et al. Prevalence of oral manifestations in 203 patients with psoriasis. J Eur Acad Dermatol Venereol JEADV. 2011;25:1481–3.CrossRef
11.
Zurück zum Zitat Löfgren CD, Wickström C, Sonesson M, Lagunas PT, Christersson C. A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health. 2012;12:29.CrossRefPubMedCentralPubMed Löfgren CD, Wickström C, Sonesson M, Lagunas PT, Christersson C. A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health. 2012;12:29.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Van der Putten G-J, Brand HS, Schols JMGA, de Baat C. The diagnostic suitability of a xerostomia questionnaire and the association between xerostomia, hyposalivation and medication use in a group of nursing home residents. Clin Oral Investig. 2011;15:185–92.CrossRefPubMedCentralPubMed Van der Putten G-J, Brand HS, Schols JMGA, de Baat C. The diagnostic suitability of a xerostomia questionnaire and the association between xerostomia, hyposalivation and medication use in a group of nursing home residents. Clin Oral Investig. 2011;15:185–92.CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Crema VO, Hamassaki DE, Santos MF. Small Rho GTPases are important for acinus formation in a human salivary gland cell line. Cell Tissue Res. 2006;325:493–500.CrossRefPubMed Crema VO, Hamassaki DE, Santos MF. Small Rho GTPases are important for acinus formation in a human salivary gland cell line. Cell Tissue Res. 2006;325:493–500.CrossRefPubMed
14.
Zurück zum Zitat Xu N, Keung B, Myat MM. Rho GTPase controls invagination and cohesive migration of the Drosophila salivary gland through Crumbs and Rho-kinase. Dev Biol. 2008;321:88–100.CrossRefPubMed Xu N, Keung B, Myat MM. Rho GTPase controls invagination and cohesive migration of the Drosophila salivary gland through Crumbs and Rho-kinase. Dev Biol. 2008;321:88–100.CrossRefPubMed
15.
Zurück zum Zitat Vallée B, Doudeau M, Godin F, Gombault A, Tchalikian A, de Tauzia M-L, et al. Nf1 RasGAP inhibition of LIMK2 mediates a new cross-talk between Ras and Rho pathways. PLoS One. 2012;7:e47283.CrossRefPubMedCentralPubMed Vallée B, Doudeau M, Godin F, Gombault A, Tchalikian A, de Tauzia M-L, et al. Nf1 RasGAP inhibition of LIMK2 mediates a new cross-talk between Ras and Rho pathways. PLoS One. 2012;7:e47283.CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, et al. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J Biol Chem. 2005;280:39524–33.CrossRefPubMed Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, et al. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J Biol Chem. 2005;280:39524–33.CrossRefPubMed
17.
Zurück zum Zitat Kimura N, Watanabe T, Fukase M, Wakita A, Noshiro T, Kimura I. Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen’s disease. Mod Pathol Off J U S Can Acad Pathol Inc. 2002;15:183–8. Kimura N, Watanabe T, Fukase M, Wakita A, Noshiro T, Kimura I. Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen’s disease. Mod Pathol Off J U S Can Acad Pathol Inc. 2002;15:183–8.
18.
Zurück zum Zitat Foster PN, Stewart M, Lowe JS, Atkinson M. Achalasia like disorder of the oesophagus in von Recklinghausen’s neurofibromatosis. Gut. 1987;28:1522–6.CrossRefPubMedCentralPubMed Foster PN, Stewart M, Lowe JS, Atkinson M. Achalasia like disorder of the oesophagus in von Recklinghausen’s neurofibromatosis. Gut. 1987;28:1522–6.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Okazaki K, Kakita A, Tanaka H, Kimura K, Minagawa M, Morita T, et al. Widespread ischemic brain lesions caused by vasculopathy associated with neurofibromatosis type 1. Neuropathol Off J Jpn Soc Neuropathol. 2010;30:627–33.CrossRef Okazaki K, Kakita A, Tanaka H, Kimura K, Minagawa M, Morita T, et al. Widespread ischemic brain lesions caused by vasculopathy associated with neurofibromatosis type 1. Neuropathol Off J Jpn Soc Neuropathol. 2010;30:627–33.CrossRef
20.
Zurück zum Zitat Danglot G, Régnier V, Fauvet D, Vassal G, Kujas M, Bernheim A. Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5′ part of the gene. Hum Mol Genet. 1995;4:915–20.CrossRefPubMed Danglot G, Régnier V, Fauvet D, Vassal G, Kujas M, Bernheim A. Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5′ part of the gene. Hum Mol Genet. 1995;4:915–20.CrossRefPubMed
Metadaten
Titel
High prevalence of hyposalivation in individuals with neurofibromatosis 1: a case–control study
verfasst von
Karin Soares Cunha
Rafaela Elvira Rozza-de-Menezes
Eloá Borges Luna
Lilian Machado de Sousa Almeida
Raquel Richelieu Lima de Andrade Pontes
Paula Nascimento Almeida
Letícia Vidaurre de Aguiar
Eliane Pedra Dias
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Orphanet Journal of Rare Diseases / Ausgabe 1/2015
Elektronische ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-015-0239-4

Weitere Artikel der Ausgabe 1/2015

Orphanet Journal of Rare Diseases 1/2015 Zur Ausgabe